Availability of addiction medications in private health plans

Journal of Substance Abuse Treatment

Volumn 34, Issue 2, 2008, Pages 147-156

  Horgan, Constance M ^a   Reif, Sharon ^a   Hodgkin, Dominic ^a   Garnick, Deborah W ^a   Merrick, Elizabeth L ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

Cost sharing; Formulary; Pharmacotherapy; Pharmacy benefits; Substance abuse

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DISULFIRAM; NALTREXONE;

ALCOHOLISM; ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULARY; DRUG TOLERABILITY; DRUG USE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL;

ALCOHOL DETERRENTS; ALCOHOLISM; BUPRENORPHINE; COST SHARING; DATA COLLECTION; DISULFIRAM; DRUGS, GENERIC; FORMULARIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 38549126107     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2007.02.004     Document Type: Article

References (31)

1. Anton R.F., and Swift R.M. Current pharmacotherapies of alcoholism: A U.S. perspective. American Journal on Addictions 12 (2003) S53-S68
2. Center for Substance Abuse Treatment. Naltrexone and alcoholism treatment (1998), Substance Abuse and Mental Health Services Administration, Rockville, MD
3. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid Addiction (2004), Substance Abuse and Mental Health Services Administration, Rockville, MD
4. Centers for Medicare and Medicaid Services. National health expenditures by type of service and source of funds, CY 1960-2004. Table 2: National health expenditures aggregate amounts and average annual percent change, by type of expenditure. Retrieved July 10, 2006, from (2006). http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage
5. Fiellin D.A., Kleber H., Trumble-Hejduk J.G., McLellan A.T., and Kosten T.R. Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment 27 (2004) 153-159
6. Frank R.G., Conti R.M., and Goldman H.W. Mental health policy and psychotropic drugs. Milbank Quarterly 83 (2005) 271-298
7. Garis R.I., Clark B.E., Siracuse M.V., and Makoid M.C. Examining the benefit of pharmacy benefit management companies. American Journal of Health-System Pharmacy 61 (2004) 81-85
8. Gleason P.P., Gunderson B.W., and Gericke K.R. Are incentive-based formularies inversely associated with drug utilization in managed care?. Annals of Pharmacotherapy 39 (2005) 339-345
9. Harris K.M., and Thomas C. Naltrexone and pharmacy benefit management. Journal of Addictive Diseases 23 (2004) 11-29
10. Hoadley J. Cost containment strategies for prescription drugs: Assessing the evidence in the literature (2005), Kaiser Family Foundation, Menlo Park, CA
11. Hodgkin D., Horgan C.M., Garnick D.W., Merrick E.L., and Volpe-Vartanian J. Management of psychotropic medications in private health plans. Clinical Therapeutics 29 (2007) 371-380
12. Horgan, C. M., Garnick, D. W., Merrick, E. L., & Hodgkin, D. (in review) Changes in how health plans provide behavioral health services. Manuscript in preparation.
13. Huskamp H.A. Managing psychotropic drug costs: Will formularies work?. Health Affairs 22 (2003) 84-96
14. Kaiser Family Foundation. Employer health benefits 2005 annual survey. Retrieved August 2, 2006, from (2005). http://www.kff.org/insurance/7315/upload/7315.pdf
15. Kemper P., Blumenthal D., Corrigan J.M., Cunningham P.J., Felt S.M., Grossman J.M., et al. The design of the community tracking study: A longitudinal study of health system change and its effects on people. Inquiry 33 (1996) 195-206
16. Landsman P.B., Yu W., Liu X., Teutsch S.M., and Berger M.L. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. American Journal of Managed Care 11 (2005) 621-628
17. Mark T.L. Are medications for alcoholism underutilized? An analysis of private-sector and Medicaid claims. Drug Benefits Trends 16 (2004) 154-158
18. Mark T.L., Coffey R.M., McKusick D., Harwood H., King E., Bouchery E., et al. National expenditures for mental health services and substance abuse treatment 1991-2001 (no. SMA 05-3999) (2005), Substance Abuse and Mental Health Services Administration, Rockville, MD
19. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., and Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 25 (2006)
20. Nair K.V., and Valuck R.J. Impact of three-tier pharmacy benefit structures on consumer attitudes, pharmacy, medical utilization and costs: A critical review. Disease Management & Health Outcomes 12 (2004) 81-92
21. National Institute of Alcohol Abuse and Alcoholism. Five year strategic plan FY07-FY11: Alcohol across the lifespan. Retrieved August 1, 2006, from (2006). http://pubs.niaaa.nih.gov/publications/StrategicPlan/NIAAASTRATEGICPLAN.htm
22. National Institute of Drug Abuse. Principles of effective treatment for criminal justice populations (2006), National Institute of Drug Abuse, Rockville, MD
23. National Quality Forum. Evidence-based treatment practices for substance use disorders: Workshop proceedings (2005), National Quality Forum, Washington, DC
24. Olson B.M. Approaches to pharmacy benefit management and the impact of consumer cost-sharing. Clinical Therapeutics 25 (2002) 250-272
25. Payte J.T., Zweben J.E., and Martin J. Opioid maintenance treatment. In: Graham A.W., Schultz T.K., Mayo-Smith M.F., Ries R.K., and Wilford B.B. (Eds). Principles of addiction medicine. 3rd ed. (2003), American Society of Addiction Medicine, Chevy Chase, MD 751-766
26. Research Triangle Institute. SUDAAN user's manual: Release 8.0 (2002), Research Triangle Institute, Research Triangle Park, NC
27. Saxon A.J., and McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology and Therapeutics 108 (2005) 119-128
28. Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: Detailed tables. Retrieved August 3, 2006, from (2005). http://www.oas.samhsa.gov/NSDUH/2k4nsduh/2k4tabs/2k4TabsCover.pdf
29. Substance Abuse and Mental Health Services Administration. 2004 National Survey on Drug Use and Health. [computer file]. Retrieved August 3, 2006, from. http://webapp.icpsr.umich.edu/cocoon/SAMHDA-SERIES/00064.xml
30. The Medical Letter. Buprenorphine: An alternative to methadone. The Medical Letter on Drugs and Therapeutics 45 (2003)
31. Volkow N.D. NIDA at 30: Committed to scientific solutions for drug addiction problems. NIDA Notes 19 (2004). http://www.drugabuse.gov/NIDA_notes/NNvol19N1/DirRepVol19N1.html Retrieved January 15, 2007, from